# Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

> **NCT02318771** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 41 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Metastatic Renal Cell Cancer
- Recurrent Head and Neck Carcinoma
- Recurrent Lung Carcinoma
- Recurrent Renal Cell Carcinoma
- Recurrent Skin Carcinoma
- Stage III Renal Cell Cancer
- Stage IV Lung Cancer
- Stage IV Skin Melanoma

## Interventions

- **RADIATION:** Radiation Therapy (RT)
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02318771
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-05
- **Primary completion:** 2018-06-05
- **Final completion:** 2021-03-25
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318771, "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02318771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*